Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study123

@inproceedings{Garvey2012TwoyearSW,
  title={Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study123},
  author={W Timothy Garvey and Donna H Ryan and Michelle Look and Kishore M Gadde and David B. Allison and C Anthony Peterson and Michael L. Schwiers and Wesley W. Day and Charles H Bowden},
  booktitle={The American journal of clinical nutrition},
  year={2012}
}
BACKGROUND Obesity is a serious chronic disease. Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has previously shown significant weight loss compared with placebo in a 56-wk study in overweight and obese subjects with ≥2 weight-related comorbidities. OBJECTIVE This study evaluated the long-term efficacy and safety of PHEN/TPM CR in overweight and obese subjects with cardiometabolic disease. DESIGN This was a placebo-controlled, double-blind… CONTINUE READING
Highly Influential
This paper has highly influenced 13 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 9 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 144 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

a position statement from the International Diabetes Federation Taskforce on Epidemiology and Prevention

  • International Diabetes Federation Consensus Panel. Bariatric surgical, procedural interventions in the treatment of obese patients w diabetes
  • Available from: http://www.sicob.org/00_materiali…
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…